As we dive into the second half of 2025, we are excited to share the collective progress made by the CLAIMS consortium in the RECLAIM clinical study (NCT06280755).
One of the key milestones we are proud to announce is the peer-reviewed publication of the RECLAIM study protocol: https://doi.org/10.3389/fneur.2025.1557947
About the Study
The RECLAIM study is a multicenter, retrospective, observational study designed to address a significant unmet need in the management of multiple sclerosis (MS): personalized, data-driven treatment optimization.
MS is characterized by a gradual worsening of disability over time. Despite the availability of numerous disease-modifying therapies, there remains a critical need for tools that can more accurately track progression and guide individualized treatment strategies. RECLAIM aims to set the stage for the development of novel biomarkers and AI-based predictive models capable of detecting and differentiating between various forms of disease progression.
At the heart of the study is the creation of a harmonized, high-quality database including real-world and trial data on MS that will support:
- The development and validation of progression-related biomarkers
- AI-driven tools to estimate individual disease trajectories
- Deeper insights into disease progression, prognosis, treatment responses, and patient subtypes.
By bringing together clinical and pharmaceutical partners, as well as experts in image processing, data science and project management, RECLAIM aims to empower clinicians with tools to more effectively monitor disease progression and personalize treatment decisions for each person living with MS.
Cohort update
Patients (clinical information)
We are also pleased to share the latest progress in cohort data collection and integration:
- Over 49,334 MRI datasets from 5,068 subjects have been successfully processed
- Clinical data from over 2,800 subjects have been collected
- Optical coherence tomography (OCT) data have been received from 168 patients.
The RECLAIM cohort currently includes individuals diagnosed with MS, CIS, RIS, NMOSD, and MOGAD, collected from five renowned clinical centers across Europe. While data uploads from these centers are still ongoing, the cohort is also being enriched with clinical trial data from two of the top 10 CNS pharmaceutical companies and one biotech. In addition, evoked potential (EP) data will be uploaded shortly. Full data collection is expected to be completed by the end of 2025.
MS-specific Common Data Model (CDM)
The collected data have undergone pseudonymization, secure transfer to a central storage infrastructure, as well as processing and analysis of both imaging and clinical data. Following this, all patient-level data were systematically linked and mapped into an MS-specific Common Data Model (CDM). The CDM was developed collaboratively across the CLAIMS consortium, and we are currently preparing a manuscript to describe its structure in detail and make it available to the wider research community.
What’s next?
We are actively validating and testing the first generation of AI-based models for MS prognosis and treatment optimization, developed using this unique dataset. We look forward to sharing further updates on the next scientific milestones!
